Latigo Biotherapeutics Secures $150 Million in Series B Funding to Propel Development of Non-Opioid…
Latigo Biotherapeutics ("Latigo"), a clinical-stage biotechnology company developing best-in-class non-opioid pain treatments that target pain at its source, announced it has closed…
Read More...
Read More...
